fbpx
TriNav

Resources & Publications

Filters
Reset
Reset
Reset
Reset
Reset
Demonstrates how TriNav’s SmartValve can be used to achieve stasis when performing DEB-TACE by modulating pressure and preventing reflux, and how PEDD can be used to achieve a good tumor response in DEB-TACE.
Demonstrates how cTACE administered via PEDD may improve therapeutic delivery and response for a previously treated tumor.
May 2015 Journal of Vascular and Interventional Radiology The Impact of an Antireflux Catheter on Target Volume Particulate Distribution in Liver-Directed Embolotherapy: A Pilot Study Pasciak et al.
September 2017 PlOS One Short-term imaging response after drug-eluting embolic trans-arterial chemoembolization delivered with the Surefire Infusion System® for the treatment of hepatocellular carcinoma Kim et al.
April 2018 Journal of Vascular and Interventional Radiology Abstract No. 133 Surefire Infusion System (SIS) hepatocellular carcinoma registry study interim results: a multicenter study of the safety, feasibility, and outcomes of the SIS expandable-tip microcatheter in DEB-TACE Kapoor et al.
January 2019 Cardiovascular and Interventional Radiology End-hole Versus Microvalve Infusion Catheters in Patients Undergoing Drug-Eluting Microspheres-TACE for Solitary Hepatocellular Carcinoma Tumors: A Retrospective Analysis Titano et al. Watch the video for more information.

Indications for Use
The TriNav and TriNav LV Infusion Systems are intended for use in angiographic procedures. They deliver radiopaque media and therapeutic agents to selected sites in the peripheral vascular system.4,5

Contraindications
TriNav and TriNav LV Infusion Systems are not indicated for use in the vasculature of the central nervous system (including the neurovasculature) or central circulatory system (including the coronary vasculature).4,5

Rx Only
For the safe and proper use of the TriNav and TriNav LV Infusion Systems, refer to their individual Instructions for Use.